Isaac Barchas Sells 83,094 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 83,094 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34. Following the completion of the transaction, the director directly owned 125,410 shares of the company’s stock, valued at approximately $3,023,635.10. This trade represents a 39.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 2.1%

Shares of Immunome stock traded up $0.49 during midday trading on Tuesday, reaching $24.39. The company had a trading volume of 1,561,508 shares, compared to its average volume of 1,722,826. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -10.25 and a beta of 2.07. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The stock has a fifty day simple moving average of $20.99 and a 200 day simple moving average of $21.83.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. Sell-side analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Creative Planning raised its stake in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Immunome by 14.4% during the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after acquiring an additional 935 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after buying an additional 1,167 shares during the period. Assetmark Inc. increased its holdings in Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its holdings in Immunome by 16.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after acquiring an additional 1,970 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on IMNM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Truist Financial raised their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a report on Friday, June 12th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.